The state-of-the-art of invasive brain-computer interfaces in humans: a systematic review and individual patient...

Objective.Invasive brain-computer interfaces (iBCIs) have evolved significantly since the first neurotrophic electrode was implanted in a human subject three decades ago. Since then, both hardware and software advances have increased the iBCI performance to enable tasks such as decoding conversations in real-time and manipulating external limb prostheses with haptic feedback. In this systematic review, we aim to evaluate the advances in iBCI hardware, software and functionality and describe challenges and opportunities in the iBCI field.Approach.Medline, EMBASE, PubMed and Cochrane databases were searched from inception until 13 April 2024. Primary studies reporting the use of iBCI in human subjects to restore function were included. Endpoints extracted include iBCI electrode type, iBCI implantation, decoder algorithm, iBCI effector, testing and training methodology and functional outcomes. Narrative synthesis of outcomes was done with a focus on hardware and software development trends over time. Individual patient data (IPD) was also collected and an IPD meta-analysis was done to identify factors significant to iBCI performance.Main results.93 studies involving 214 patients were included in this systematic review. The median task performance accuracy for cursor control tasks was 76.00% (Interquartile range [IQR] = 21.2), for motor tasks was 80.00% (IQR = 23.3), and for communication tasks was 93.27% (IQR = 15.3). Current advances in iBCI software include use of recurrent neural network architectures as decoders, while hardware advances such as intravascular stentrodes provide a less invasive alternative for neural recording. Challenges include the lack of standardized testing paradigms for specific functional outcomes and issues with portability and chronicity limiting iBCI usage to laboratory settings.Significance.Our systematic review demonstrated the exponential rate at which iBCIs have evolved over the past two decades. Yet, more work is needed for widespread clinical adoption and translation to long-term home-use.